prior,O
infection,CAUSE_OF_DEATH
to,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
Eric,PERSON
J.,PERSON
Nilles,PERSON
.1.2,O
*,O
Elizabeth,PERSON
W.,PERSON
Karlson,PERSON
.1.2,NUMBER
*,O
Maia,PERSON
Norman,PERSON
.1.2.3.4,NUMBER
Tal,O
Gilboa,O
.1.2.4,NUMBER
Stephanie,PERSON
Fischinger,O
.5,O
Caroline,PERSON
Atyeo,PERSON
.5,O
Guohai,O
Zhou,O
.1.2,NUMBER
Christopher,PERSON
L.,PERSON
Ben,PERSON
‐,PERSON
nett,O
.1.2.6,O
Nicole,PERSON
V.,PERSON
Tolan,PERSON
.1.2,O
Karina,PERSON
Oganezova,PERSON
.1,O
David,PERSON
R.,PERSON
Walt,PERSON
.1.2.4,NUMBER
Galit,O
Alter,O
.2.5.7,O
Daimon,PERSON
P.,PERSON
Simmons,PERSON
.1.2,O
Peter,PERSON
Schur,PERSON
.1.2,O
Petr,PERSON
Jarolim,PERSON
.1.2,O
Lindsey,PERSON
R.,PERSON
Baden,PERSON
.1.2,O
Brigham,LOCATION
and,O
Wom,O
‐,O
ens,O
Hospital,O
.,O
Boston,CITY
.,O
MA,ORGANIZATION
Massachusetts,ORGANIZATION
General,ORGANIZATION
Hospital,ORGANIZATION
.,O
Boston,CITY
.,O
MA,STATE_OR_PROVINCE
Keywords,O
:,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
.,O
COVID,O
‐,O
19,NUMBER
.,O
serology,O
.,O
antibodies,O
.,O
im,O
‐,O
munoassays,O
Running,O
title,O
:,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
immunoassay,O
assessment,O
Cor,O
‐,O
respondence,O
:,O
Eric,PERSON
Nilles,PERSON
.,O
Brigham,ORGANIZATION
and,O
Womens,ORGANIZATION
Hospital,ORGANIZATION
.,O
75,NUMBER
Francis,PERSON
St.,LOCATION
.,O
Boston,CITY
02115,DATE
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
immunoassays,O
can,O
be,O
valuable,O
tools,O
for,O
informing,O
the,O
global,O
response,O
.,O
but,O
many,O
currently,DATE
available,O
assays,O
have,O
not,O
been,O
independently,O
validated,O
.,O
We,O
conducted,O
a,O
per,O
‐,O
formance,O
assessment,O
of,O
four,NUMBER
assays,O
including,O
the,O
Roche,O
Diagnos,O
‐,O
tics,O
and,O
Epitope,ORGANIZATION
Diagnostics,ORGANIZATION
immunoassays,O
.,O
Seroepidemiology,O
is,O
an,O
important,O
tool,O
to,O
characterize,O
the,O
epidemiology,O
and,O
immunobi,O
‐,O
ology,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
but,O
many,O
immunoassays,O
have,O
not,O
been,O
external,O
‐,O
ly,O
validated,O
raising,O
questions,O
about,O
reliability,O
of,O
study,O
find,O
‐,O
ings,O
.,O
To,O
ensure,O
meaningful,O
data,O
.,O
particularly,O
in,O
a,O
low,O
seropreva,O
‐,O
lence,O
population,O
.,O
assays,O
need,O
to,O
be,O
rigorously,O
characterized,O
with,O
high,O
specificity,O
.,O
232,NUMBER
pre,O
‐,O
pandemic,O
negative,O
controls,O
.,O
Sensitivi,O
‐,O
ty,O
was,O
stratified,O
by,O
time,O
from,O
symptom,O
onset,O
.,O
The,O
Simoa,O
multi,O
‐,O
plex,O
assay,O
applied,O
three,NUMBER
pre,O
‐,O
defined,O
algorithm,O
models,O
to,O
deter,O
‐,O
mine,O
sample,O
The,O
Roche,PERSON
and,O
Ragon,PERSON
/,O
MGH,O
IgG,O
assays,O
each,O
registered,O
1/232,NUMBER
false,O
positive,O
.,O
the,O
primary,O
Simoa,O
model,TITLE
registered,O
2/232,NUMBER
false,O
positives,O
.,O
and,O
the,O
Epitope,ORGANIZATION
registered,O
2/230,NUMBER
and,O
3/230,NUMBER
false,O
positives,O
for,O
the,O
IgG,O
and,O
IgM,O
assays,O
respectively,O
.,O
Sensitivity,O
>,O
21,DURATION
days,DURATION
post,O
symptom,O
‐,O
onset,O
was,O
100,PERCENT
%,PERCENT
for,O
all,O
assays,O
except,O
Epi,PERSON
‐,PERSON
tope,O
IgM,O
.,O
but,O
lower,O
and,O
/,O
or,O
with,O
greater,O
variability,O
between,O
as,O
‐,O
says,O
for,O
samples,O
collected,O
9,NUMBER
‐,O
14,DURATION
days,DURATION
(,O
67,NUMBER
‐,O
100,PERCENT
%,PERCENT
),O
and,O
15,NUMBER
‐,O
21,DURATION
days,DURATION
(,O
69,NUMBER
‐,O
100,PERCENT
%,PERCENT
),O
post,O
‐,O
symptom,O
onset,O
.,O
The,O
Simoa,O
and,O
Epitope,O
IgG,O
assays,O
demonstrated,O
excellent,O
sensitivity,O
earlier,O
in,O
the,O
disease,CAUSE_OF_DEATH
course,O
.,O
The,O
Roche,PERSON
and,O
Ragon,PERSON
/,O
MGH,O
assays,O
were,O
less,O
sensitive,O
during,O
early,O
disease,CAUSE_OF_DEATH
.,O
particularly,O
among,O
immunosuppressed,O
individuals,O
.,O
The,O
Epitope,O
IgG,O
demonstrated,O
good,O
sensitivity,O
and,O
specificity,O
.,O
The,O
Roche,PERSON
and,O
Ragon,PERSON
/,O
MGH,O
IgG,O
assays,O
registered,O
rare,O
false,O
positives,O
with,O
lower,O
early,O
sensitivity,O
.,O
The,O
Simoa,O
assay,O
primary,O
model,TITLE
had,O
excellent,O
sensitivity,O
and,O
few,O
false,O
positives,O
.,O
In,O
response,O
to,O
the,O
rapid,O
global,O
spread,O
of,O
a,O
novel,O
virus,O
.,O
severe,O
acute,O
respirato,O
‐,O
ry,O
syndrome,O
2,NUMBER
acute,O
or,O
prior,O
infection,CAUSE_OF_DEATH
with,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
.,O
Serologi,O
‐,O
cal,O
assays,O
to,O
detect,O
antibodies,O
to,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
have,O
received,O
at,O
‐,O
tention,O
due,O
to,O
the,O
large,O
number,O
of,O
immunoassays,O
being,O
used,O
for,O
a,O
range,O
of,O
purposes,O
despite,O
suboptimal,O
validation,O
[,O
13,NUMBER
],O
.,O
Immunoas,O
‐,O
says,O
are,O
powerful,O
tools,O
that,O
can,O
be,O
used,O
to,O
characterize,O
the,O
epi,O
‐,O
demiology,O
and,O
convalescent,O
plasma,O
donors,O
[,O
9,NUMBER
],O
.,O
and,O
potentially,O
provide,O
additional,O
approaches,O
for,O
the,O
clinical,O
diagnosis,O
of,O
acute,O
infection,CAUSE_OF_DEATH
[,O
10,NUMBER
],O
.,O
Seroepidemiological,O
uses,O
of,O
these,O
tools,O
are,O
nu,O
‐,O
merous,O
and,O
include,O
characterizing,O
population,O
‐,O
level,O
seroprevalence,O
[,O
6,NUMBER
],O
;,O
identifying,O
the,O
fraction,O
of,O
asymptomatic,O
and,O
unreported,O
in,O
‐,O
fections,O
[,O
11,NUMBER
],O
;,O
informing,O
group,O
‐,O
specific,O
and,O
population,O
‐,O
level,O
con,O
‐,O
trol,O
interventions,O
[,O
12,NUMBER
],O
;,O
monitoring,O
transmission,O
dynamics,O
and,O
the,O
impact,O
of,O
control,O
interventions,O
over,O
time,O
[,O
6.13,NUMBER
],O
;,O
and,O
informing,O
core,O
epidemiological,O
parameters,O
such,O
as,O
the,O
basic,O
and,O
effective,O
reproductive,O
numbers,O
and,O
infection,CAUSE_OF_DEATH
and,O
case,O
fatality,O
rates,O
[,O
1417,DATE
],O
.,O
Serology,O
‐,O
based,O
cohort,O
studies,O
that,O
combine,O
classical,O
seroepidemiological,O
approaches,O
with,O
deep,O
immune,O
profiling,O
can,O
characterize,O
the,O
nature,O
and,O
kinetics,O
of,O
the,O
humoral,O
response,O
and,O
inform,O
key,O
questions,O
including,O
risks,O
for,O
reinfection,O
and,O
the,O
pa,O
‐,O
rameters,O
of,O
protective,O
titers,O
However,O
.,O
despite,O
enormous,O
potential,O
to,O
guide,O
the,O
global,O
COVID,O
‐,O
19,NUMBER
response,O
.,O
confidence,O
in,O
serological,O
tests,O
and,O
consequently,O
the,O
results,O
of,O
seroepidemiological,O
studies,O
have,O
been,O
undermined,O
by,O
poor,O
(,O
or,O
poorly,O
defined,O
),O
test,O
character,O
‐,O
istics,O
[,O
3,NUMBER
],O
.,O
Given,O
the,O
importance,O
of,O
vigorous,O
and,O
independent,RELIGION
im,O
‐,O
munoassay,O
cross,O
validation,O
.,O
we,O
report,O
on,O
the,O
performance,O
of,O
two,NUMBER
Ethical,O
considerations,O
The,O
use,O
of,O
study,O
samples,O
and,O
data,O
was,O
ap,O
‐,O
proved,O
by,O
the,O
Mass,STATE_OR_PROVINCE
General,TITLE
Brigham,ORGANIZATION
(,O
MGB,O
),O
Study,O
design,O
Study,O
sam,O
‐,O
ples,O
Two,NUMBER
panels,O
of,O
positive,O
and,O
negative,O
control,O
samples,O
were,O
se,O
‐,O
lected,O
from,O
the,O
MGB,ORGANIZATION
Biobank,ORGANIZATION
.,O
a,O
biorepository,O
that,O
contains,O
bio,O
‐,O
logical,O
samples,O
and,O
linked,O
demographic,O
and,O
clinical,O
data,O
from,O
>,O
117.000,NUMBER
patients,O
enrolled,O
through,O
the,O
MGB,O
network,O
[,O
19,NUMBER
],O
.,O
Posi,O
‐,O
tive,O
control,O
panel,O
:,O
To,O
assess,O
sensitivity,O
.,O
we,O
selected,O
68,NUMBER
posi,O
‐,O
tive,O
control,O
samples,O
from,O
28,NUMBER
patients,O
that,O
had,O
been,O
hospitalized,O
at,O
the,O
Brigham,LOCATION
and,O
Womens,ORGANIZATION
Hospital,ORGANIZATION
(,O
BWH,O
),O
between,O
March,DATE
30,DATE
and,O
May,DATE
4,NUMBER
.,O
2020,DATE
.,O
and,O
that,O
previously,DATE
tested,O
positive,O
by,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
rever,O
‐,O
setranscriptase,O
polymerase,O
chain,O
reaction,O
(,O
RT,O
‐,O
PCR,O
),O
.,O
Samples,O
were,O
collected,O
a,O
mean,O
of,O
10.5,DURATION
days,DURATION
(,O
standard,O
deviation,O
6.0,DURATION
days,DURATION
),O
post,O
‐,O
RT,O
‐,O
PCR,O
confirmation,O
and,O
16.1,DURATION
days,DURATION
(,O
standard,O
deviation,O
5.4,DURATION
days,DURATION
),O
post,O
‐,O
symptom,O
onset,O
(,O
PSO,O
),O
.,O
The,O
median,O
number,O
of,O
samples,O
per,O
indi,O
‐,O
vidual,O
was,O
two,NUMBER
(,O
range,O
1,NUMBER
‐,O
5,NUMBER
),O
and,O
the,O
median,O
interval,O
between,O
sample,O
collection,O
was,O
three,DURATION
days,DURATION
(,O
range,O
2,NUMBER
‐,O
6,DURATION
days,DURATION
),O
.,O
The,O
Negative,O
control,O
panel,O
:,O
To,O
assess,O
specificity,O
.,O
we,O
selected,O
232,NUMBER
prepandemic,O
nega,O
‐,O
tive,O
control,O
samples,O
from,O
the,O
MGB,ORGANIZATION
Biobank,ORGANIZATION
collected,O
between,O
Au,O
‐,O
gust,O
28,NUMBER
.,O
2017,DATE
and,O
September,DATE
26,DATE
.,DATE
2019,DATE
.,O
The,O
median,O
age,O
was,O
55,NUMBER
years,DURATION
(,O
range,O
20,NUMBER
‐,O
89,NUMBER
),O
and,O
90/232,NUMBER
(,O
39,PERCENT
%,PERCENT
),O
were,O
female,O
.,O
To,O
determine,O
if,O
recent,O
respiratory,CAUSE_OF_DEATH
infections,CAUSE_OF_DEATH
may,O
be,O
associated,O
with,O
increased,O
cross,O
‐,O
reactivity,O
and,O
false,O
positives,O
.,O
we,O
selected,O
negative,O
con,O
‐,O
trols,O
with,O
and,O
without,O
recent,O
respiratory,CAUSE_OF_DEATH
infections,CAUSE_OF_DEATH
.,O
Of,O
the,O
to,O
‐,O
tal,O
232,NUMBER
negative,O
control,O
samples,O
.,O
100,NUMBER
were,O
from,O
individuals,O
with,O
‐,O
out,O
recent,O
respiratory,O
illness,CAUSE_OF_DEATH
;,O
31,NUMBER
from,O
individuals,O
with,O
prior,O
laboratory,O
‐,O
confirmed,O
respiratory,CAUSE_OF_DEATH
infections,CAUSE_OF_DEATH
;,O
101,NUMBER
from,O
individuals,O
with,O
a,O
recent,O
clinical,O
diagnosis,O
of,O
respiratory,CAUSE_OF_DEATH
infections,CAUSE_OF_DEATH
in,O
‐,O
cluding,O
upper,O
respiratory,O
based,O
on,O
diagnoses,O
recorded,O
in,O
the,O
electronic,O
health,O
record,O
between,O
1,NUMBER
and,O
31,DURATION
days,DURATION
prior,O
to,O
sample,O
collection,O
.,O
To,O
ensure,O
valid,O
comparison,O
between,O
assays,O
and,O
given,O
differences,O
in,O
plasma,O
/,O
sera,O
requirements,O
according,O
to,O
manufactur,O
‐,O
er,O
/,O
assay,O
specifications,O
.,O
we,O
only,O
selected,O
controls,O
with,O
both,O
serum,O
and,O
plasma,O
available,O
from,O
the,O
same,O
individual,O
and,O
time,O
point,O
.,O
All,O
samples,O
were,O
stored,O
at,O
‐,O
80C,O
following,O
sample,O
process,O
‐,O
ing,O
and,O
none,O
underwent,O
thaw,O
‐,O
refreezing,O
cycles,O
prior,O
to,O
analysis,O
.,O
Except,O
for,O
sample,O
type,O
(,O
i.e.,O
serum,O
or,O
plasma,O
),O
.,O
identical,O
panels,O
of,O
positive,O
and,O
negative,O
controls,O
were,O
provided,O
to,O
each,O
of,O
the,O
four,NUMBER
participating,O
laboratories,O
(,O
with,O
two,NUMBER
fewer,O
samples,O
provided,O
to,O
one,NUMBER
lab,O
),O
.,O
Samples,O
were,O
blinded,O
to,O
all,O
laboratory,O
staff,O
and,O
were,O
only,O
unblinded,O
after,O
results,O
were,O
provided,O
to,O
the,O
principal,TITLE
investigators,O
.,O
Clinical,O
data,O
We,O
searched,O
an,O
electronic,O
health,O
records,O
system,O
linked,O
to,O
the,O
Biobank,O
to,O
extract,O
demographic,O
data,O
for,O
all,O
controls,O
and,O
clinical,O
data,O
for,O
positive,O
controls,O
.,O
includ,O
‐,O
ing,O
chronic,O
medical,O
conditions,O
.,O
level,O
of,O
care,O
(,O
non,O
‐,O
ICU,O
versus,O
ICU,O
),O
.,O
and,O
date,O
of,O
RT,O
‐,O
PCR,O
test,O
.,O
Two,NUMBER
study,O
investigators,O
included,O
cough,O
.,O
fever,CAUSE_OF_DEATH
.,O
dyspnea,O
.,O
myalgias,O
.,O
new,O
loss,O
of,O
taste,O
or,O
smell,O
.,O
or,O
sore,O
throat,O
.,O
Serological,O
assays,O
and,O
protocols,O
We,O
assessed,O
the,O
performance,O
of,O
four,NUMBER
immunoassays,O
including,O
(,O
i,O
),O
Elecsys,O
Anti,O
‐,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
(,O
Roche,ORGANIZATION
Diagnostics,ORGANIZATION
.,O
Indianapolis,CITY
.,O
USA,COUNTRY
),O
immunoassay,O
intended,O
for,O
the,O
qualitative,O
detection,O
of,O
antibodies,O
against,O
the,O
nucleo,O
‐,O
capsid,O
(,O
NC,ORGANIZATION
),O
antigen,O
[,O
20,NUMBER
],O
(,O
thought,O
to,O
include,O
IgG,O
.,O
IgM,O
.,O
and,O
IgA,O
.,O
although,O
IgM,O
and,O
IgA,O
are,O
not,O
specified,O
in,O
product,O
information,O
),O
;,O
(,O
ii,O
),O
EDI,O
New,O
Coronavirus,O
COVID19,O
enzyme,O
‐,O
linked,O
immunosorbent,O
as,O
‐,O
says,O
(,O
ELISA,ORGANIZATION
),O
(,O
Epitope,ORGANIZATION
Diagnostics,ORGANIZATION
.,O
USA,COUNTRY
),O
that,O
detect,O
IgG,O
against,O
the,O
NC,STATE_OR_PROVINCE
antigen,O
[,O
21,NUMBER
],O
and,O
IgM,O
against,O
an,O
unspecified,O
antigen,O
[,O
22,NUMBER
],O
;,O
(,O
iii,O
),O
Ragon,ORGANIZATION
/,ORGANIZATION
MGH,ORGANIZATION
inhouse,O
ELISA,O
that,O
detects,O
IgG,O
.,O
IgM,O
and,O
IgA,O
against,O
the,O
receptor,O
binding,O
domain,O
(,O
RBD,O
),O
;,O
and,O
(,O
iv,O
),O
the,O
Single,O
Molecule,O
Array,O
multiplex,O
assay,O
(,O
Simoa,PERSON
),O
that,O
detects,O
IgG,O
.,O
IgM,O
.,O
and,O
IgA,O
against,O
the,O
spike,O
protein,O
.,O
S1,O
subunit,O
.,O
RBD,O
.,O
and,O
NC,ORGANIZATION
[,O
10,NUMBER
],O
.,O
The,O
Ragon,PERSON
/,O
MGH,O
assay,O
was,O
performed,O
at,O
the,O
Ragon,PERSON
assays,O
were,O
performed,O
according,O
to,O
manufacturer,TITLE
specifications,O
.,O
The,O
Simoa,O
and,O
Ragon,PERSON
/,O
MGH,O
assays,O
were,O
performed,O
according,O
to,O
previously,DATE
described,O
methods,O
[,O
10.23,NUMBER
],O
.,O
Result,O
classification,O
Threshold,O
cutoffs,O
for,O
defining,O
positive,O
.,O
negative,O
or,O
indeterminate,O
/,O
borderline,O
test,O
results,O
were,O
laboratories,O
prior,O
to,O
the,O
study,O
.,O
The,O
Ragon,PERSON
/,O
MGH,O
positive,O
cutoff,O
was,O
equal,O
to,O
the,O
mean,O
of,O
the,O
OD,O
‐,O
converted,O
ug,O
/,O
ml,O
values,O
of,O
the,O
negative,O
control,O
wells,O
on,O
the,O
respective,O
plate,O
plus,O
three,NUMBER
times,O
the,O
standard,O
deviation,O
of,O
the,O
concentration,O
from,O
over,O
100,NUMBER
pre,O
‐,O
pandemic,O
plasma,O
samples,O
.,O
Background,O
‐,O
corrected,O
concentrations,O
were,O
divided,O
by,O
the,O
cutoff,O
to,O
generate,O
signalto,O
‐,O
cutoff,O
(,O
S,O
/,O
CO,STATE_OR_PROVINCE
),O
ratios,O
.,O
Samples,O
with,O
S,O
/,O
CO,STATE_OR_PROVINCE
values,O
greater,O
than,O
1.0,NUMBER
were,O
considered,O
posi,O
‐,O
tive,O
.,O
Given,O
the,O
Simoa,LOCATION
multiplex,O
assay,O
includes,O
12,NUMBER
output,O
mea,O
‐,O
sures,O
per,O
sample,O
(,O
IgG,O
.,O
IgM,O
.,O
and,O
IgA,O
against,O
four,NUMBER
viral,O
epitopes,O
),O
.,O
result,O
determination,O
was,O
based,O
upon,O
three,NUMBER
pre,O
‐,O
study,O
classifica,O
‐,O
tion,O
models,O
trained,O
using,O
an,O
independent,RELIGION
panel,O
of,O
142,NUMBER
positive,O
samples,O
by,O
RT,O
‐,O
PCR,O
SARS,O
‐,O
Cov,O
‐,O
2,NUMBER
and,O
200,NUMBER
negative,O
pre,O
‐,O
pandemic,O
con,O
‐,O
trols,O
.,O
Two,NUMBER
models,O
used,O
cross,O
‐,O
validation,O
to,O
select,O
the,O
fewest,O
num,O
‐,O
ber,O
of,O
informative,O
markers,O
.,O
An,O
Early,O
Model,TITLE
encompassed,O
all,O
posi,O
‐,O
tive,O
RT,O
‐,O
PCR,O
timepoints,O
within,O
one,DURATION
week,DURATION
following,O
the,O
positive,O
RT,O
‐,O
PCR,O
in,O
pre,O
‐,O
pandemic,O
controls,O
.,O
This,O
cross,O
‐,O
validation,O
yielded,O
four,NUMBER
markers,O
(,O
IgA,O
S1,O
.,O
IgA,O
Nucleocapsid,O
.,O
IgG,O
Nucleocapsid,O
.,O
and,O
IgG,O
Spike,PERSON
),O
and,O
exhibited,O
the,O
best,O
performance,O
in,O
the,O
training,O
set,O
[,O
10,NUMBER
],O
.,O
A,O
Late,O
Model,TITLE
encompassed,O
all,O
RT,O
‐,O
PCR,O
positive,O
timepoints,O
af,O
‐,O
ter,TITLE
one,DURATION
week,DURATION
since,O
PCR,O
against,O
all,O
pre,O
‐,O
pandemic,O
controls,O
.,O
This,O
cross,O
‐,O
validation,O
yielded,O
only,O
a,O
single,O
marker,TITLE
IgA,O
S1,O
.,O
The,O
model,TITLE
‐,O
specific,O
threshold,O
for,O
a,O
positive,O
test,O
result,O
was,O
determined,O
based,O
on,O
the,O
cutoff,O
that,O
yielded,O
100,PERCENT
%,PERCENT
specificity,O
in,O
the,O
training,O
set,O
.,O
A,O
third,ORDINAL
model,TITLE
was,O
a,O
simple,O
12,NUMBER
Parameter,O
logistic,O
regression,O
using,O
all,O
12,NUMBER
outputs,O
.,O
Data,O
analysis,O
We,O
performed,O
five,NUMBER
primary,O
independent,RELIGION
analyses,O
.,O
One,NUMBER
each,O
for,O
the,O
Roche,O
(,O
which,O
provides,O
a,O
single,O
result,O
for,O
all,O
isotypes,O
),O
and,O
Ragon,PERSON
/,O
MGH,O
(,O
IgG,O
),O
assays,O
;,O
two,NUMBER
for,O
the,O
Epitope,O
immunoassays,O
(,O
IgG,O
and,O
IgM,O
),O
;,O
and,O
one,NUMBER
for,O
the,O
pri,O
‐,O
mary,O
Simoa,O
assay,O
Early,O
Model,TITLE
.,O
Analyses,O
of,O
the,O
Ragon,O
IgA,O
/,O
IgM,O
and,O
Simoa,O
Late,O
Model,TITLE
and,O
12,NUMBER
‐,O
Parameter,O
Model,TITLE
are,O
included,O
in,O
supple,O
‐,O
mentary,O
materials,O
.,O
Indeterminate,O
or,O
borderline,O
results,O
were,O
con,O
‐,O
sidered,O
negative,O
for,O
all,O
analyses,O
.,O
We,O
determined,O
sensitivity,O
us,O
‐,O
ing,O
positive,O
controls,O
and,O
specificity,O
using,O
negative,O
controls,O
as,O
the,O
gold,O
standard,O
.,O
Sensitivity,O
was,O
calculated,O
independently,O
for,O
samples,O
collected,O
8,NUMBER
‐,O
14,NUMBER
.,O
15,NUMBER
‐,O
21,NUMBER
.,O
and,O
>,O
21,DURATION
days,DURATION
from,O
symptom,O
onset,O
.,O
Assay,O
agreement,O
was,O
calculated,O
between,O
the,O
Roche,LOCATION
.,O
Ragon,PERSON
/,O
MGH,O
IgG,O
.,O
Epitope,ORGANIZATION
IgG,O
.,O
and,O
Simoa,O
Early,O
Model,TITLE
using,O
prevalence,O
‐,O
adjusted,O
and,O
bias,O
‐,O
adjusted,O
Kappa,O
[,O
24,NUMBER
],O
.,O
Binomial,O
exact,O
95,PERCENT
%,PERCENT
confidence,O
intervals,O
were,O
calculated,O
for,O
all,O
estimates,O
.,O
All,O
analyses,O
Specificity,O
:,O
The,O
Roche,PERSON
and,O
Ragon,PERSON
/,O
MGH,O
(,O
IgG,O
),O
assays,O
registered,O
1/232,NUMBER
false,O
positive,O
for,O
specificities,O
of,O
99.6,PERCENT
%,PERCENT
(,O
95,PERCENT
%,PERCENT
CI,O
98.7,NUMBER
‐,O
100,PERCENT
%,PERCENT
),O
.,O
The,O
Epitope,O
IgG,O
and,O
IgM,O
assays,O
registered,O
2/230,NUMBER
and,O
3/230,NUMBER
false,O
positives,O
for,O
specificities,O
of,O
99.1,PERCENT
%,PERCENT
(,O
97.9,NUMBER
‐,O
100,PERCENT
%,PERCENT
),O
and,O
98.6,PERCENT
%,PERCENT
(,O
95,PERCENT
%,PERCENT
CI,O
97.2,PERCENT
%,PERCENT
‐,O
100,PERCENT
%,PERCENT
),O
respectively,O
.,O
No,O
Epitope,O
false,O
positives,O
overlapped,O
and,O
therefore,O
if,O
combining,O
the,O
two,NUMBER
assays,O
to,O
provide,O
a,O
single,O
result,O
.,O
the,O
specificity,O
is,O
lower,O
(,O
5/230,NUMBER
false,O
positives,O
;,O
97.8,PERCENT
%,PERCENT
[,O
95,PERCENT
%,PERCENT
CI,O
95.9100,PERCENT
%,PERCENT
],O
),O
.,O
The,O
Simoa,O
Early,O
Model,TITLE
registered,O
2/232,NUMBER
false,O
posi,O
‐,O
tives,O
with,O
a,O
specificity,O
of,O
99.1,PERCENT
%,PERCENT
(,O
95,PERCENT
%,PERCENT
94,PERCENT
%,PERCENT
and,O
70,PERCENT
%,PERCENT
respectively,O
;,O
Simoa,O
Late,O
and,O
12,NUMBER
‐,O
marker,TITLE
models,O
demonstrated,O
specificities,O
of,O
98.7,PERCENT
%,PERCENT
and,O
94,PERCENT
%,PERCENT
(,O
supplemental,O
data,O
),O
.,O
Of,O
the,O
combined,O
nine,NUMBER
false,O
positives,O
results,O
(,O
Roche,ORGANIZATION
[,O
1,NUMBER
],O
.,O
Ragon,PERSON
/,O
MGH,O
IgG,O
[,O
1,NUMBER
],O
.,O
Epitope,ORGANIZATION
IgG,O
[,O
2,NUMBER
],O
and,O
IgM,O
[,O
3,NUMBER
],O
.,O
and,O
Simoa,O
Early,O
Model,TITLE
[,O
2,NUMBER
],O
),O
.,O
five,NUMBER
were,O
from,O
100,NUMBER
nega,O
‐,O
tive,O
controls,O
without,O
recent,O
respiratory,CAUSE_OF_DEATH
infection,CAUSE_OF_DEATH
and,O
four,NUMBER
from,O
132,NUMBER
negative,O
controls,O
with,O
recent,O
respiratory,CAUSE_OF_DEATH
infection,CAUSE_OF_DEATH
.,O
suggest,O
‐,O
ing,O
cross,O
reactivity,O
due,O
to,O
recent,O
respiratory,CAUSE_OF_DEATH
infections,CAUSE_OF_DEATH
is,O
un,O
‐,O
likely,O
to,O
be,O
an,O
important,O
cause,O
of,O
false,O
positives,O
in,O
these,O
as,O
‐,O
says,O
.,O
No,O
common,O
coronaviruses,O
(,O
e.g.,O
229E,O
.,O
NL63,O
.,O
OC43,O
or,O
HKU1,O
),O
were,O
documented,O
among,O
these,O
samples,O
.,O
however,O
.,O
so,O
these,O
data,O
do,O
not,O
assess,O
for,O
common,O
coronavirus,O
‐,O
specific,O
cross,O
reactivity,O
.,O
Sensitivities,O
:,O
All,O
assays,O
except,O
the,O
Epitope,O
IgM,O
demonstrated,O
100,PERCENT
%,PERCENT
sensitivity,O
among,O
samples,O
For,O
the,O
remaining,O
time,O
periods,O
.,O
the,O
Simoa,ORGANIZATION
Early,ORGANIZATION
Model,ORGANIZATION
registered,O
the,O
fewest,O
false,O
negatives,O
and,O
highest,O
sensitivities,O
.,O
However,O
.,O
confidence,O
intervals,O
generally,O
overlapped,O
across,O
assays,O
included,O
in,O
the,O
primary,O
analyses,O
except,O
for,O
the,O
earlier,O
time,O
periods,O
when,O
the,O
Simoa,O
Early,O
4,NUMBER
),O
.,O
At,O
21,DURATION
days,DURATION
PSO,ORGANIZATION
.,O
the,O
Ragon,ORGANIZATION
/,ORGANIZATION
MGH,ORGANIZATION
IgM,ORGANIZATION
and,O
IgA,O
assays,O
demonstrated,O
sensitivities,O
of,O
77.8,PERCENT
%,PERCENT
and,O
100,PERCENT
%,PERCENT
respectively,O
;,O
Simoa,O
Late,O
and,O
12,NUMBER
‐,O
paremeter,O
mod,O
‐,O
els,O
demonstrated,O
100,PERCENT
%,PERCENT
sensitivity,O
individuals,O
that,O
subsequently,O
seroconverted,O
;,O
6/12,NUMBER
were,O
from,O
three,NUMBER
individuals,O
that,O
were,O
receiv,O
‐,O
ing,O
immunosuppressive,O
therapy,O
;,O
and,O
2/12,NUMBER
were,O
collected,O
at,O
11,NUMBER
and,O
18,DURATION
days,DURATION
PSO,ORGANIZATION
from,O
patients,O
without,O
subsequent,O
sample,O
collections,O
.,O
Of,O
seven,NUMBER
Roche,PERSON
false,O
negatives,O
.,O
2/7,NUMBER
were,O
from,O
individuals,O
that,O
seroconverted,O
in,O
later,O
samples,O
;,O
3/7,NUMBER
samples,O
were,O
from,O
two,NUMBER
pa,O
‐,O
tients,O
receiving,O
immunosuppressive,O
therapy,O
;,O
and,O
the,O
remaining,O
2/7,NUMBER
were,O
from,O
the,O
same,O
patient,O
collected,O
16,NUMBER
and,O
18,DURATION
days,DURATION
PSO,ORGANIZATION
.,O
Of,O
two,NUMBER
Epitope,O
IgG,O
false,O
negatives,O
.,O
one,NUMBER
later,O
seroconverted,O
and,O
one,NUMBER
was,O
immunosuppressed,O
.,O
Of,O
25,NUMBER
Epitope,ORGANIZATION
IgM,O
false,O
negatives,O
.,O
5/25,NUMBER
later,O
seroconverted,O
.,O
6/25,NUMBER
were,O
immunosuppressed,O
.,O
and,O
14/25,NUMBER
were,O
col,O
‐,O
lected,O
10,NUMBER
‐,O
37,DURATION
days,DURATION
PSO,ORGANIZATION
.,O
The,O
Simoa,O
Early,O
Model,TITLE
registered,O
only,O
one,NUMBER
false,O
negative,O
that,O
seroconverted,O
in,O
later,O
samples,O
.,O
When,O
exclud,O
‐,O
ing,O
individuals,O
receiving,O
immunosuppressive,O
therapy,O
and,O
early,O
samples,O
individuals,O
that,O
subsequently,O
seroconverted,O
.,O
there,O
were,O
no,O
false,O
negatives,O
for,O
the,O
Simoa,O
assay,O
or,O
Epitope,O
IgG,O
assays,O
.,O
two,NUMBER
false,O
negatives,O
apiece,O
for,O
the,O
Ragon,ORGANIZATION
/,ORGANIZATION
MGH,ORGANIZATION
and,O
Roche,O
assays,O
.,O
and,O
14,NUMBER
false,O
negatives,O
for,O
the,O
Epitope,ORGANIZATION
IgM,O
assay,O
.,O
Assay,O
agreement,O
:,O
In,O
‐,O
ter,TITLE
‐,O
assay,O
concordance,O
for,O
negative,O
controls,O
was,O
high,O
for,O
all,O
com,O
‐,O
binations,O
of,O
assays,O
with,O
the,O
highest,O
agreement,O
between,O
Roche,LOCATION
and,O
Ragon,PERSON
/,O
MGH,O
IgG,O
assays,O
(,O
Kappa,O
0.98,NUMBER
.,O
95,PERCENT
%,PERCENT
CI,O
0.94,NUMBER
‐,O
1.00,NUMBER
),O
and,O
the,O
low,O
‐,O
est,O
between,O
Epitope,ORGANIZATION
IgG,O
and,O
Simoa,O
Early,O
Model,TITLE
(,O
Kappa,O
0.97,NUMBER
.,O
95,PERCENT
%,PERCENT
CI,O
0.91,NUMBER
‐,O
0.99,NUMBER
),O
.,O
Of,O
nine,NUMBER
total,O
false,O
positives,O
across,O
the,O
five,NUMBER
assays,O
none,O
were,O
overlapping,O
between,O
assays,O
.,O
Inter,O
‐,O
assay,O
agreement,O
for,O
positive,O
controls,O
was,O
more,O
variable,O
and,O
ranged,O
from,O
Kappa,O
0.94,NUMBER
(,O
95,PERCENT
%,PERCENT
CI,O
0.80,NUMBER
‐,O
0.99,NUMBER
),O
between,O
the,O
Simoa,LOCATION
and,O
Epitope,O
IgG,O
assays,O
to,O
0.68,NUMBER
(,O
95,PERCENT
%,PERCENT
CI,O
0.46,NUMBER
‐,O
0.83,NUMBER
),O
between,O
the,O
Ragon,LOCATION
/,O
MGH,O
IgG,O
and,O
Epitope,O
IgG,O
and,O
Roche,O
assays,O
.,O
Lower,O
concordance,O
between,O
positive,O
controls,O
was,O
largely,O
driven,O
by,O
the,O
higher,O
numbers,O
of,O
false,O
negatives,O
observed,O
in,O
the,O
Ragon,LOCATION
/,O
MGH,O
IgG,O
and,O
Roche,O
assays,O
.,O
Of,O
the,O
20,NUMBER
discrete,O
false,O
negative,O
results,O
.,O
10,NUMBER
overlapped,O
between,O
one,NUMBER
or,O
more,O
assay,O
.,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
immunoassays,O
using,O
a,O
panel,O
of,O
300,NUMBER
well,O
characterized,O
con,O
‐,O
trol,O
samples,O
including,O
68,NUMBER
positive,O
control,O
samples,O
from,O
28,NUMBER
RT,O
‐,O
PCR,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
confirmed,O
hospitalized,O
patients,O
and,O
232,NUMBER
pre,O
‐,O
pandemic,O
negative,O
control,O
samples,O
that,O
included,O
132,NUMBER
samples,O
from,O
individu,O
‐,O
als,O
with,O
recent,O
respiratory,CAUSE_OF_DEATH
infections,CAUSE_OF_DEATH
.,O
We,O
assessed,O
the,O
sensitiv,O
‐,O
ity,O
.,O
specificity,O
.,O
and,O
agreement,O
between,O
assays,O
using,O
pre,O
‐,O
defined,O
thresholds,O
and,O
methods,O
.,O
Because,O
the,O
sensitivity,O
of,O
serological,O
assays,O
is,O
dependent,O
on,O
when,O
samples,O
are,O
collected,O
relative,O
to,O
symptom,O
onset,O
.,O
we,O
stratified,O
assay,O
sensitivity,O
by,O
time,O
from,O
symp,O
‐,O
tom,O
onset,O
to,O
sample,O
collection,O
.,O
To,O
our,O
knowledge,O
.,O
this,O
is,O
the,O
first,ORDINAL
immunoassay,O
and,O
includes,O
a,O
comprehensive,O
evaluation,O
of,O
the,O
EDI,O
Epitope,O
assays,O
.,O
Unlike,O
most,O
head,O
to,O
head,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
im,O
‐,O
munoasssay,O
performance,O
evaluations,O
.,O
unique,O
patient,O
‐,O
sample,O
combi,O
‐,O
nations,O
were,O
used,O
for,O
all,O
assays,O
.,O
All,O
four,NUMBER
assays,O
performed,O
well,O
with,O
small,O
absolute,O
differences,O
between,O
them,O
.,O
The,O
Roche,PERSON
and,O
Ragon,PERSON
/,O
MGH,O
immunoassays,O
registered,O
the,O
lowest,O
number,O
of,O
false,O
pos,O
‐,O
itives,O
(,O
1/232,NUMBER
),O
for,O
a,O
specificity,O
of,O
99.6,PERCENT
%,PERCENT
(,O
95,PERCENT
%,PERCENT
CI,O
98.7,NUMBER
‐,O
100,PERCENT
%,PERCENT
),O
.,O
These,O
findings,O
align,O
with,O
the,O
Roche,ORGANIZATION
assay,O
package,O
insert,O
(,O
10/5272,NUMBER
false,O
positives,O
.,O
specificity,O
99.81,PERCENT
%,PERCENT
[,O
95,PERCENT
%,PERCENT
CI,O
99.65,NUMBER
‐,O
99.91,PERCENT
%,PERCENT
],O
),O
[,O
20,NUMBER
],O
and,O
confirm,O
excellent,O
specificity,O
.,O
The,O
Simoa,O
Early,O
Model,TITLE
and,O
Epi,O
‐,O
tope,O
IgM,O
assay,O
registered,O
two,NUMBER
false,O
positives,O
apiece,O
with,O
slight,O
‐,O
ly,O
lower,O
specificity,O
(,O
99.1,PERCENT
%,PERCENT
[,O
95,PERCENT
%,PERCENT
CI,O
97.9,NUMBER
‐,O
100,PERCENT
%,PERCENT
],O
),O
.,O
although,O
with,O
overlapping,O
confidence,O
intervals,O
;,O
the,O
Epitope,O
IgM,O
performed,O
less,O
well,O
with,O
lower,O
specificity,O
.,O
as,O
did,O
other,O
Simoa,O
models,O
and,O
the,O
Ragon,PERSON
/,O
MGH,ORGANIZATION
IgM,ORGANIZATION
and,O
IgA,O
assays,O
.,O
The,O
Epitope,O
IgG,O
assay,O
specificity,O
in,O
this,O
study,O
was,O
higher,O
than,O
other,O
recent,O
studies,O
that,O
reported,O
specificities,O
of,O
88.7,PERCENT
%,PERCENT
from,O
53,NUMBER
negative,O
controls,O
[,O
25,NUMBER
],O
and,O
89.8,PERCENT
%,PERCENT
from,O
108,NUMBER
negative,O
controls,O
[,O
23,NUMBER
],O
.,O
The,O
overall,O
performance,O
of,O
Epi,O
‐,O
tope,O
is,O
superior,O
when,O
considering,O
only,O
the,O
single,O
IgG,O
rather,O
than,O
combining,O
the,O
IgG,O
and,O
IgM,O
assays,O
.,O
Given,O
that,O
even,O
small,O
decreases,O
in,O
specificity,O
can,O
substantially,O
decrease,O
the,O
positive,O
predictive,O
value,O
(,O
PPV,O
),O
.,O
particularly,O
in,O
populations,O
with,O
low,O
pre,O
‐,O
test,O
proba,O
‐,O
bilities,O
or,O
with,O
low,O
true,O
disease,CAUSE_OF_DEATH
prevalence,O
.,O
our,O
findings,O
sug,O
‐,O
gest,O
the,O
Epitope,O
IgG,O
assay,O
alone,O
is,O
preferable,O
.,O
particularly,O
if,O
used,O
for,O
seroepidemiological,O
purposes,O
.,O
For,O
example,O
.,O
when,O
testing,O
a,O
population,O
with,O
a,O
3,PERCENT
%,PERCENT
true,O
prevalence,O
of,O
disease,CAUSE_OF_DEATH
with,O
a,O
test,O
that,O
is,O
98,PERCENT
%,PERCENT
specific,O
.,O
the,O
PPV,O
will,O
be,O
approximately,O
60,PERCENT
%,PERCENT
and,O
an,O
estimated,O
four,NUMBER
in,O
ten,NUMBER
positive,O
results,O
will,O
be,O
false,O
positives,O
.,O
Conversely,O
.,O
if,O
using,O
a,O
test,O
that,O
is,O
99.5,PERCENT
%,PERCENT
specific,O
applied,O
to,O
the,O
same,O
population,O
.,O
the,O
PPV,O
is,O
approximately,O
85,PERCENT
%,PERCENT
and,O
slightly,O
over,O
one,NUMBER
in,O
seven,NUMBER
positive,O
results,O
will,O
be,O
false,O
positives,O
.,O
Given,O
that,O
most,O
populations,O
globally,O
are,O
assumed,O
to,O
have,O
low,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
seroprevalence,O
.,O
likely,O
<,O
5,PERCENT
%,PERCENT
with,O
substantial,O
heterogeneity,O
.,O
small,O
differences,O
in,O
test,O
specificity,O
are,O
of,O
critical,O
importance,O
With,O
the,O
exception,O
of,O
Epitope,ORGANIZATION
IgM,ORGANIZATION
.,O
all,O
assays,O
demonstrated,O
100,PERCENT
%,PERCENT
sensi,O
‐,O
tivity,O
among,O
samples,O
collected,O
>,O
21,DURATION
days,DURATION
PSO,ORGANIZATION
.,O
although,O
only,O
nine,NUMBER
samples,O
were,O
included,O
from,O
this,O
time,O
period,O
.,O
The,O
sensitivity,O
was,O
lower,O
with,O
greater,O
variability,O
between,O
assays,O
for,O
samples,O
col,O
‐,O
lected,O
earlier,O
after,O
symptom,O
onset,O
.,O
This,O
is,O
to,O
be,O
expected,O
given,O
serological,O
assays,O
for,O
most,O
pathogens,O
including,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
are,O
well,O
described,O
as,O
having,O
poor,O
sensitivity,O
earlier,O
in,O
disease,CAUSE_OF_DEATH
course,O
.,O
Current,DATE
reported,O
data,O
suggests,O
the,O
mean,O
interval,O
from,O
symptom,O
‐,O
onset,O
to,O
seroconversion,O
for,O
SARSCoV,O
‐,O
2,NUMBER
is,O
~,O
13,DURATION
days,DURATION
for,O
both,O
IgM,O
and,O
IgG,O
.,O
although,O
substantial,O
heterogeneity,O
exists,O
be,O
‐,O
tween,O
individuals,O
and,O
assays,O
;,O
by,O
25,NUMBER
‐,O
27,DURATION
days,DURATION
PSO,ORGANIZATION
.,O
98,NUMBER
‐,O
100,PERCENT
%,PERCENT
of,O
cases,O
are,O
expected,O
to,O
be,O
seropositive,O
by,O
most,O
serological,O
assays,O
[,O
26.27,NUMBER
],O
.,O
By,O
comparison,O
.,O
the,O
assays,O
in,O
this,O
study,O
demonstrated,O
67,NUMBER
‐,O
100,PERCENT
%,PERCENT
sensitivity,O
for,O
samples,O
collected,O
between,O
8,NUMBER
‐,O
14,DURATION
days,DURATION
PSO,O
and,O
69,NUMBER
‐,O
100,PERCENT
%,PERCENT
sensitivity,O
for,O
samples,O
collected,O
15,NUMBER
‐,O
21,DURATION
days,DURATION
PSO,ORGANIZATION
.,O
The,O
Simoa,O
Early,O
Model,TITLE
assay,O
demonstrated,O
exellent,O
sensitivity,O
during,O
the,O
earlier,O
PSO,ORGANIZATION
windows,O
.,O
The,O
sensitivity,O
of,O
the,O
Roche,O
assay,O
was,O
slightly,O
higher,O
during,O
earlier,O
periods,O
and,O
slightly,O
lower,O
later,O
compared,O
to,O
data,O
reported,O
by,O
the,O
manufacturer,TITLE
;,O
Roche,ORGANIZATION
reported,O
66,PERCENT
%,PERCENT
.,O
88,PERCENT
%,PERCENT
and,O
100,PERCENT
%,PERCENT
sensitivity,O
at,O
0,NUMBER
‐,O
6,NUMBER
.,O
7,NUMBER
‐,O
13,NUMBER
and,O
14,DURATION
days,DURATION
post,O
‐,O
PCR,O
confirmation,O
[,O
20,NUMBER
],O
.,O
versus,O
our,O
findings,O
of,O
71,PERCENT
%,PERCENT
.,O
95,PERCENT
%,PERCENT
.,O
and,O
94,PERCENT
%,PERCENT
using,O
the,O
same,O
time,O
and,O
date,O
‐,O
from,O
PCR,O
‐,O
confirmation,O
criteria,O
(,O
data,O
not,O
shown,O
),O
.,O
The,O
sensitivity,O
of,O
the,O
Epitope,O
IgG,O
assay,O
was,O
lower,O
than,O
package,O
insert,O
data,O
that,O
report,O
100,PERCENT
%,PERCENT
for,O
30,NUMBER
positive,O
controls,O
in,O
the,DATE
second,DATE
week,DATE
of,O
disease,CAUSE_OF_DEATH
[,O
21,NUMBER
],O
and,O
lower,O
than,O
a,O
German,NATIONALITY
study,O
that,O
reported,O
100,PERCENT
%,PERCENT
sensitivity,O
for,O
22,NUMBER
positive,O
controls,O
[,O
25,NUMBER
],O
but,O
higher,O
but,O
with,O
overlapping,O
confidence,O
intervals,O
for,O
one,NUMBER
US,COUNTRY
‐,O
based,O
study,O
that,O
reported,O
sensitivities,O
of,O
84,PERCENT
%,PERCENT
at,O
6,NUMBER
‐,O
20,DURATION
days,DURATION
and,O
91,PERCENT
%,PERCENT
at,O
>,O
20,DURATION
days,DURATION
[,O
23,NUMBER
],O
.,O
This,O
study,O
has,O
several,O
limitations,O
.,O
Although,O
this,O
study,O
was,O
based,O
on,O
well,O
characterized,O
controls,O
.,O
we,O
can,O
not,O
defini,O
‐,O
tively,O
extrapolate,O
findings,O
to,O
other,O
populations,O
[,O
28,NUMBER
],O
.,O
For,O
exam,O
‐,O
ple,O
.,O
the,O
sensitivity,O
of,O
these,O
assays,O
was,O
assessed,O
in,O
samples,O
from,O
RT,O
‐,O
PCR,O
confirmed,O
hospitalized,O
patients,O
with,O
samples,O
collected,O
a,O
mean,O
of,O
16,DURATION
days,DURATION
(,O
SD,STATE_OR_PROVINCE
5,NUMBER
),O
after,O
symptom,O
onset,O
.,O
Given,O
most,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
infections,CAUSE_OF_DEATH
are,O
mild,O
or,O
asymptomatic,O
and,O
do,O
not,O
require,O
hospital,O
‐,O
ization,O
.,O
and,O
given,O
that,O
little,O
is,O
known,O
about,O
humoral,O
kinetics,O
>,O
2,NUMBER
months,DURATION
post,O
infection,CAUSE_OF_DEATH
.,O
the,O
sensitivity,O
of,O
these,O
assays,O
may,O
be,O
lower,O
in,O
individuals,O
>,O
2,DURATION
months,DURATION
post,O
‐,O
infection,CAUSE_OF_DEATH
and,O
/,O
or,O
individuals,O
with,O
mild,O
or,O
asymptomatic,O
infections,CAUSE_OF_DEATH
that,O
likely,O
mount,O
less,O
durable,O
immune,O
responses,O
[,O
26.28,NUMBER
],O
.,O
We,O
did,O
not,O
include,O
negative,O
control,O
samples,O
from,O
individuals,O
with,O
confirmed,O
common,O
coron,O
‐,O
aviruses,O
.,O
which,O
may,O
increase,O
cross,O
reactivity,O
and,O
false,O
posi,O
‐,O
tives,O
.,O
Our,O
study,O
findings,O
align,O
with,O
manufacturer,TITLE
data,O
for,O
the,O
Roche,ORGANIZATION
Diagnostics,ORGANIZATION
Elecsys,ORGANIZATION
Anti,ORGANIZATION
‐,O
SARSCoV,O
‐,O
2,NUMBER
IgG,O
immunoassay,O
and,O
con,O
‐,O
firm,O
that,O
false,O
positives,O
are,O
rare,O
.,O
specificity,O
is,O
high,O
.,O
and,O
sen,O
‐,O
sitivity,O
is,O
excellent,O
>,O
3,DURATION
weeks,DURATION
after,O
symptom,O
onset,O
.,O
but,O
lower,O
early,O
in,O
the,O
disease,CAUSE_OF_DEATH
course,O
and,O
among,O
immunocompromised,O
individu,O
‐,O
als,O
.,O
The,O
Epitope,ORGANIZATION
Diagnostics,ORGANIZATION
IgG,O
immunoassay,O
has,O
lower,O
specifici,O
‐,O
ty,O
and,O
sensitivity,O
than,O
data,O
released,O
by,O
the,O
manufacturer,TITLE
.,O
but,O
overall,O
performed,O
well,O
with,O
few,O
false,O
positives,O
and,O
high,O
sensi,O
‐,O
tivity,O
.,O
The,O
Epitope,O
IgM,O
had,O
more,O
false,O
positives,O
and,O
lower,O
sensi,O
‐,O
tivity,O
and,O
given,O
IgM,O
does,O
not,O
appear,O
to,O
rise,O
substantially,O
earli,O
‐,O
er,O
than,O
IgG,O
in,O
SARSCoV,O
‐,O
2,NUMBER
infections,CAUSE_OF_DEATH
[,O
26,NUMBER
],O
.,O
the,O
Epitope,O
IgM,O
assay,O
may,O
not,O
add,O
value,O
to,O
the,O
IgG,O
assay,O
alone,O
.,O
The,O
Ragon,PERSON
/,O
MGH,O
IgG,O
im,O
‐,O
munoassay,O
largely,O
aligned,O
with,O
the,O
Roche,O
assay,O
and,O
false,O
posi,O
‐,O
tives,O
were,O
rare,O
.,O
specificity,O
was,O
high,O
.,O
and,O
sensitivity,O
was,O
excel,O
‐,O
lent,O
more,DURATION
than,DURATION
three,DURATION
weeks,DURATION
post,O
‐,O
infection,CAUSE_OF_DEATH
but,O
lower,O
earlier,O
in,O
disease,CAUSE_OF_DEATH
course,O
and,O
among,O
immunosuppressed,O
individuals,O
.,O
The,O
Simoa,PERSON
Early,O
Model,TITLE
demonstrated,O
high,O
specificity,O
and,O
excellent,O
sensitiv,O
‐,O
ity,O
.,O
Characterizing,O
the,O
epidemiology,O
and,O
immunobiology,O
is,O
a,O
key,O
priority,O
for,O
informing,O
and,O
responding,O
to,O
the,O
current,DATE
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
pandemic,O
.,O
For,O
this,O
we,O
need,O
test,O
performance,O
studies,O
such,O
as,O
this,O
to,O
reliably,O
and,O
independently,O
validate,O
immunoassays,O
.,O
Krammer,PERSON
F,O
.,O
Simon,PERSON
V.,PERSON
Serology,PERSON
assays,O
to,O
manage,O
COVID,O
‐,O
19,NUMBER
.,O
Science,O
.,O
2020,DATE
;,O
Peth,PERSON
‐,O
erick,O
A.,O
Developing,O
antibody,O
tests,O
for,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
.,O
Lancet,O
[,O
Inter,O
‐,O
net,O
],O
.,O
Theel,ORGANIZATION
ES,ORGANIZATION
.,O
Slev,PERSON
P,O
.,O
Wheeler,O
S,O
.,O
Couturier,O
MR,O
.,O
Wong,PERSON
SJ,O
.,O
Kad,O
‐,O
khoda,PERSON
K,PERSON
.,O
The,O
Role,O
of,O
Antibody,O
Testing,O
for,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
:,O
Is,O
There,O
One,NUMBER
?,O
J,PERSON
Clin,PERSON
Microbiol,PERSON
[,O
Internet,MISC
],O
.,O
2020,DATE
;,O
(,O
April,DATE
),O
:,O
115,NUMBER
.,O
Lipsitch,O
M,O
.,O
Swerdlow,PERSON
DL,O
.,O
Finelli,PERSON
L.,PERSON
Defining,PERSON
the,O
epidemiology,O
of,O
Covid,O
‐,O
19,NUMBER
‐,O
Studies,O
needed,O
.,O
N,O
Engl,O
J,O
Med,O
[,O
Internet,MISC
],O
.,O
2020,DATE
;,O
382:11946,NUMBER
.,O
Avail,O
‐,O
able,O
from,O
:,O
multicohort,O
study,O
.,O
The,O
Lancet,O
Microbe,O
[,O
Internet,MISC
],O
.,O
2020,DATE
;,O
5247,DATE
(,O
20,NUMBER
),O
:,O
18,NUMBER
.,O
Available,O
from,O
:,O
Stringhini,PERSON
S,PERSON
.,O
Wisniak,O
A,O
.,O
Piu,O
‐,O
matti,PERSON
G,PERSON
.,O
Azman,PERSON
AS,STATE_OR_PROVINCE
.,O
Lauer,ORGANIZATION
SA,ORGANIZATION
.,O
Baysson,PERSON
H,PERSON
.,O
et,O
al,O
.,O
Repeated,O
sero,O
‐,O
prevalence,O
of,O
anti,O
‐,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
IgG,O
antibodies,O
in,O
a,O
population,O
‐,O
based,O
sample,O
from,O
Geneva,CITY
.,O
Switzerland,COUNTRY
.,O
medRxiv,O
[,O
Internet,MISC
],O
.,O
2020,DATE
;,O
Available,O
from,O
:,O
Long,O
QX,O
.,O
Liu,PERSON
BZ,PERSON
.,O
Deng,PERSON
HJ,PERSON
.,O
Wu,PERSON
GC,PERSON
.,O
Deng,PERSON
K,PERSON
.,O
Chen,PERSON
YK,PERSON
.,O
et,O
al,O
.,O
Antibody,O
responses,O
to,O
SARSCoV,O
‐,O
2,NUMBER
in,O
patients,O
with,O
COVID,O
‐,O
19,NUMBER
.,O
Nat,MISC
Med,MISC
[,MISC
Internet,MISC
],O
.,O
2020,DATE
;,O
Available,O
from,O
:,O
Wu,PERSON
F,PERSON
.,O
Wang,O
A,O
.,O
Liu,PERSON
M,O
.,O
Wang,PERSON
Q,O
.,O
Chen,PERSON
J,PERSON
.,O
Xia,PERSON
S,O
.,O
et,O
al,O
.,O
Neutralizing,O
Antibody,O
Responses,O
to,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
in,O
a,O
COVID,O
‐,O
19,NUMBER
Recovered,O
Patient,O
Cohort,O
and,O
Their,O
Im,O
‐,O
plications,O
.,O
SSRN,PERSON
Duan,PERSON
K,PERSON
.,O
Liu,PERSON
B,O
.,O
Li,PERSON
C,PERSON
.,O
Zhang,PERSON
H,PERSON
.,O
Yu,PERSON
T,PERSON
.,O
Qu,PERSON
J,PERSON
.,O
et,O
al,O
.,O
Effectiveness,O
of,O
convalescent,O
plasma,O
therapy,O
in,O
severe,O
COVID,O
‐,O
19,NUMBER
patients,O
.,O
Proc,O
Natl,O
Acad,O
Sci,O
U,O
S,O
A,O
[,O
Internet,MISC
],O
.,O
Norman,PERSON
M,PERSON
.,O
Gilboa,PERSON
T,O
.,O
Ogata,ORGANIZATION
AF,ORGANIZATION
.,O
Maley,PERSON
AM,O
.,O
Cohen,PERSON
L,O
.,O
Cai,O
Y,O
.,O
et,O
al,O
.,O
Ultra,O
‐,O
Sensitive,O
HighResolution,O
Profiling,O
of,O
Anti,O
‐,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
Antibodies,O
for,O
De,O
‐,O
tecting,O
Early,O
Seroconversion,O
in,O
COVID,O
‐,O
19,NUMBER
Patients,O
.,O
medRxiv,O
[,O
In,O
‐,O
ternet,O
],O
.,O
2020,DATE
Jan,DATE
1,DATE
;,O
2020.04.28.20083691,NUMBER
.,O
Available,O
from,O
:,O
Fontanet,PERSON
A,O
.,O
Tondeur,PERSON
L,PERSON
.,O
Madec,O
Y,O
.,O
Grant,PERSON
R,PERSON
.,O
Besombes,O
C,O
.,O
Jolly,O
N,O
.,O
et,O
al,O
.,O
Clus,O
‐,O
ter,TITLE
of,O
COVID,O
‐,O
19,NUMBER
in,O
northern,O
France,COUNTRY
:,O
A,O
retrospective,O
closed,O
cohort,O
study,O
.,O
medRxiv,O
[,O
Internet,MISC
],O
.,O
2020,DATE
;,O
2020.04.18.20071134,NUMBER
.,O
Available,O
from,O
:,O
Lipsitch,O
M,O
.,O
Kahn,PERSON
R,PERSON
.,O
Mina,PERSON
MJ,PERSON
.,O
Antibody,O
testing,O
will,O
enhance,O
the,O
power,O
and,O
accuracy,O
of,O
COVID,O
‐,O
19,NUMBER
‐,O
prevention,O
trials,O
[,O
Internet,MISC
],O
.,O
Nature,O
Medicine,O
.,O
2020,DATE
.,O
Available,O
from,O
:,O
Kucharski,PERSON
AJ,PERSON
.,O
Kama,PERSON
M,PERSON
.,O
Wat,O
‐,O
son,O
CH,COUNTRY
.,O
Aubry,PERSON
M,O
.,O
Funk,ORGANIZATION
S,ORGANIZATION
.,O
Henderson,ORGANIZATION
AD,ORGANIZATION
.,O
et,O
al,O
.,O
Using,O
paired,O
serol,O
‐,O
ogy,O
and,O
surveillance,O
data,O
to,O
quantify,O
dengue,O
transmission,O
and,O
control,O
during,O
a,O
large,O
outbreak,O
in,O
Fiji,COUNTRY
.,O
Elife,MISC
[,MISC
Internet,MISC
],O
.,O
2018,DATE
;,O
Available,O
from,O
:,O
Ioannidis,PERSON
J,PERSON
.,O
The,O
infection,CAUSE_OF_DEATH
fatality,O
rate,O
of,O
COVID,O
‐,O
19,NUMBER
inferred,O
from,O
seroprevalence,O
data,O
.,O
Hay,O
JA,O
.,O
Minter,PERSON
A,O
.,O
Ainslie,ORGANIZATION
KEC,ORGANIZATION
.,O
Lessler,PERSON
J,PERSON
.,O
Yang,PERSON
B,PERSON
.,O
Cummings,PERSON
DAT,PERSON
.,O
et,O
al,O
.,O
An,O
open,O
source,O
tool,O
to,O
infer,O
epidemiological,O
and,O
immunological,O
dynamics,O
from,O
serological,O
data,O
:,O
Serosolver,O
.,O
PLOS,O
Comput,O
Biol,O
[,O
Internet,MISC
],O
.,O
2020,DATE
;,O
Available,O
from,O
:,O
Kucharski,PERSON
AJ,PERSON
.,O
Russell,ORGANIZATION
TW,ORGANIZATION
.,O
Diamond,ORGANIZATION
C,ORGANIZATION
.,O
Liu,PERSON
Y,O
.,O
Edmunds,PERSON
J,PERSON
.,O
Funk,PERSON
S,PERSON
.,O
et,O
al,O
.,O
Early,O
dynamics,O
of,O
transmission,O
and,O
con,O
‐,O
trol,O
of,O
COVID,O
‐,O
19,NUMBER
:,O
a,O
mathematical,O
modelling,O
study,O
.,O
Lancet,O
Infect,O
Dis,PERSON
Kucharski,PERSON
AJ,PERSON
.,O
Funk,PERSON
S,PERSON
.,O
Eggo,O
RM,O
.,O
Mallet,PERSON
H,O
‐,O
P,O
.,O
Edmunds,PERSON
WJ,O
.,O
Nilles,PERSON
EJ,O
.,O
Transmission,ORGANIZATION
Dynamics,ORGANIZATION
of,ORGANIZATION
Zika,ORGANIZATION
Virus,ORGANIZATION
in,O
Island,O
Populations,O
:,O
A,O
Modelling,O
Analysis,O
of,O
the,O
2013,DATE
?,O
14,NUMBER
French,NATIONALITY
Polynesia,O
Outbreak,O
.,O
PLoS,O
Negl,PERSON
Trop,PERSON
Dis,PERSON
.,O
2016,DATE
;,O
10,NUMBER
(,O
5,NUMBER
),O
.,O
Huang,PERSON
AT,O
.,O
Garcia,PERSON
‐,O
Carreras,O
B,O
.,O
Hitch,O
‐,O
ings,O
MDT,O
.,O
Yang,PERSON
B,PERSON
.,O
Katzelnick,PERSON
L,PERSON
.,O
Rattigan,PERSON
SM,O
.,O
et,O
al,O
.,O
A,O
correlates,O
of,O
protection,O
.,O
and,O
association,O
of,O
antibody,O
responses,O
with,O
severi,O
‐,O
ty,O
of,O
disease,CAUSE_OF_DEATH
.,O
medRxiv,O
[,O
Internet,MISC
],O
.,O
2020,DATE
;,O
Available,O
from,O
:,O
Karlson,PERSON
EW,O
.,O
Boutin,PERSON
NT,STATE_OR_PROVINCE
.,O
Hoffnagle,ORGANIZATION
AG,ORGANIZATION
.,O
Allen,ORGANIZATION
NL,ORGANIZATION
.,O
Building,O
the,O
partners,O
healthcare,O
biobank,O
at,O
partners,O
personalized,O
medicine,O
:,O
Informed,O
consent,O
.,O
return,O
of,O
research,O
results,O
.,O
recruitment,O
lessons,O
and,O
op,O
‐,O
erational,O
considerations,O
.,O
J,O
Pers,O
Med,O
.,O
2016,DATE
;,O
6,NUMBER
(,O
1,NUMBER
),O
:,O
111,NUMBER
.,O
Elecsys,O
An,O
‐,O
ti,O
‐,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
Elecsys,O
Anti,O
‐,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
[,O
package,O
insert,O
],O
.,O
Basel,CITY
.,O
Roche,O
EDI,O
Novel,O
Coronavirus,O
COVID,O
‐,O
19,NUMBER
IgG,O
ELISA,O
[,O
Package,O
Insert,O
],O
.,O
San,CITY
Diego,CITY
.,O
Epitope,O
EDI,O
Novel,O
Coronavirus,O
COVID,O
‐,O
19,NUMBER
IgM,O
ELISA,O
[,O
Package,O
Insert,O
],O
.,O
San,CITY
Diego,CITY
.,O
Epitope,PERSON
Whitman,PERSON
JD,PERSON
.,O
Hiatt,PERSON
J,PERSON
.,O
Mowery,PERSON
CT,STATE_OR_PROVINCE
.,O
Shy,O
BR,O
.,O
Yu,PERSON
R,PERSON
.,O
Yamamoto,PERSON
TN,STATE_OR_PROVINCE
.,O
et,O
al,O
.,O
Test,O
performance,O
evaluation,O
of,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
serological,O
assays,O
.,O
medRxiv,O
[,O
Internet,MISC
],O
.,O
2020,DATE
Jan,DATE
1,NUMBER
;,O
2020.04.25.20074856,NUMBER
.,O
Available,O
from,O
:,O
Byrt,PERSON
T,O
.,O
Bishop,PERSON
J,PERSON
.,O
Carlin,PERSON
JB,O
.,O
Bias,O
.,O
prevalence,O
and,O
kappa,O
.,O
J,PERSON
Clin,PERSON
Epidemiol,PERSON
.,O
1993,DATE
;,O
46,NUMBER
(,O
5,NUMBER
),O
:,O
423,NUMBER
Krttgen,PERSON
A,O
.,O
Cornelissen,PERSON
CG,PERSON
.,O
Dreher,PERSON
M,O
.,O
Hornef,PERSON
M,O
.,O
Imhl,O
M,O
.,O
Kleines,O
M.,O
Comparison,O
of,O
[,O
Internet,MISC
],O
.,O
2020,DATE
;,O
128,NUMBER
(,O
April,DATE
),O
:,O
104394,NUMBER
.,O
Available,O
from,O
:,O
Borremans,MISC
B,O
.,O
Gamble,MISC
A,MISC
.,O
Prager,PERSON
K,PERSON
.,O
Helman,ORGANIZATION
SK,ORGANIZATION
.,O
McClain,ORGANIZATION
AM,ORGANIZATION
.,O
Cox,ORGANIZATION
C,ORGANIZATION
.,O
et,O
al,O
.,O
Quantifying,O
antibody,O
kinetics,O
and,O
RNA,O
shedding,O
during,O
early,O
‐,O
phase,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
infection,CAUSE_OF_DEATH
.,O
OSF,ORGANIZATION
Prepr,ORGANIZATION
.,O
Zhao,PERSON
J,PERSON
.,O
Yuan,O
Q,O
.,O
Wang,PERSON
H,PERSON
.,O
Liu,PERSON
W,PERSON
.,O
Liao,PERSON
X,PERSON
.,O
Su,O
Y,O
.,O
et,O
al,O
.,O
Antibody,O
responses,O
to,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
in,O
patients,O
of,O
novel,O
coronavirus,O
disease,CAUSE_OF_DEATH
2019,DATE
.,O
Clin,O
Infect,O
Dis,O
.,O
2020,DATE
;,O
122,NUMBER
.,O
ahead,O
print,O
30,DATE
May,DATE
2020,DATE
[,O
Internet,MISC
],O
.,O
2020,DATE
;,O
Available,O
from,O
:,O
This,O
work,O
was,O
largely,O
funded,O
by,O
Brigham,ORGANIZATION
Health,ORGANIZATION
.,O
EN,O
is,O
sup,O
‐,O
ported,O
by,O
a,O
CDC,O
U01,O
GH002238,O
.,O
LB,O
is,O
supported,O
by,O
NIH,O
UM1AI069412,O
and,O
UL1TR001102,O
.,O
D.S.,O
is,O
supported,O
by,O
NIH,ORGANIZATION
K08,O
AR075850,O
.,O
Positive,O
controls,O
Asian,NATIONALITY
or,O
Pacific,O
Islander,O
American,NATIONALITY
Indian,NATIONALITY
or,O
Alaskan,MISC
Na,MISC
‐,O
tive,O
Other,O
or,O
not,O
recorded,O
Other,O
or,O
not,O
recorded,O
Coronary,O
artery,O
disease,CAUSE_OF_DEATH
Diabetes,CAUSE_OF_DEATH
mellitus,CAUSE_OF_DEATH
Liver,CAUSE_OF_DEATH
disease,CAUSE_OF_DEATH
Other,O
immune,O
compromised,O
conditions,O
Cerebrovascular,MISC
accident,CAUSE_OF_DEATH
Age,O
in,O
year,DURATION
.,O
median,O
Female,O
sex,O
.,O
N,O
(,O
%,O
),O
Race,O
.,O
N,O
(,O
%,O
),O
Ethnicity,O
.,O
N,O
(,O
%,O
),O
Level,O
of,O
care2,O
Intensive,O
care,O
Past,DATE
medical,O
history,O
.,O
N,O
(,O
%,O
),O
2,NUMBER
.,O
Samples,O
were,O
considered,O
In,O
‐,O
tensive,O
care,O
if,O
they,O
were,O
collected,O
from,O
patients,O
that,O
required,O
ICU,O
admission,O
at,O
any,O
point,O
during,O
hospitalization,O
.,O
Only,O
hospital,O
‐,O
ized,O
patients,O
provided,O
positive,O
control,O
samples,O
.,O
therefore,O
the,O
non,O
‐,O
ICU,O
fraction,O
is,O
one,NUMBER
minus,O
the,O
proportion,O
of,O
ICU,O
.,O
COPD,O
Chron,O
‐,O
ic,O
obstructive,O
pulmonary,O
disease,CAUSE_OF_DEATH
Recent,O
acute,O
illness,CAUSE_OF_DEATH
Upper,O
res,O
‐,O
piratory,O
tract,O
Bacterial,O
pneumonia,CAUSE_OF_DEATH
Viral,O
pneumonia,CAUSE_OF_DEATH
Unspecified,O
pneumonia,CAUSE_OF_DEATH
Confirmed,O
viral,O
respiratory,O
infection1,O
Days,DURATION
prior,O
to,O
sample,O
N,O
/,O
A,O
Not,O
applicable,O
or,O
not,O
available,O
1,NUMBER
Includes,O
Parain,O
‐,O
fluenza,O
antigen,O
positive,O
(,O
n,O
=,O
13,NUMBER
),O
.,O
Metapneumovirus,O
antigen,O
(,O
10,NUMBER
),O
.,O
influenza,CAUSE_OF_DEATH
A,O
/,O
B,O
antigen,O
(,O
8,NUMBER
),O
.,O
Influenza,CAUSE_OF_DEATH
A,O
PCR,O
(,O
3,NUMBER
),O
.,O
Influenza,CAUSE_OF_DEATH
B,O
PCR,O
(,O
1,NUMBER
),O
.,O
RSV,O
antigen,O
(,O
n,O
=,O
5,NUMBER
),O
.,O
RSV,O
PCR,O
(,O
1,NUMBER
),O
.,O
Adenovirus,O
antigen,O
(,O
3,NUMBER
),O
.,O
Her,O
‐,O
pes,O
Simplex,O
I,O
(,O
DFA,O
),O
.,O
Total,O
number,O
add,O
up,O
to,O
more,O
than,O
31,NUMBER
as,O
some,O
individuals,O
recorded,O
>,O
1,NUMBER
positive,O
result,O
.,O
No,O
.,O
of,O
negative,O
No,O
.,O
testing,O
negative,O
Epitope,ORGANIZATION
IgG,ORGANIZATION
Epitope,ORGANIZATION
IgM,ORGANIZATION
1,NUMBER
.,O
Given,O
limited,O
nega,O
‐,O
tive,O
control,O
aliquots,O
.,O
the,O
Epitope,O
assays,O
were,O
tested,O
against,O
230,NUMBER
samples,O
.,O
versus,O
232,NUMBER
for,O
the,O
remaining,O
assays,O
2,NUMBER
.,O
For,O
specificity,O
of,O
Ragon,PERSON
/,O
MGH,ORGANIZATION
IgM,ORGANIZATION
and,O
IgA,O
see,O
supplementary,O
materials,O
.,O
3,NUMBER
.,O
The,O
Roche,ORGANIZATION
Elecsys,ORGANIZATION
Anti,ORGANIZATION
‐,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
immunoassay,O
detects,O
IgG,O
and,O
likely,O
IgM,O
and,O
IgA,O
;,O
details,O
of,O
other,O
isotypes,O
are,O
not,O
provided,O
by,O
manu,O
‐,O
facturer,O
4,NUMBER
.,O
Specificity,O
of,O
the,O
Simoa,O
multiplex,O
assay,O
Early,O
Model,TITLE
.,O
For,O
specificities,O
of,O
the,O
Late,O
and,O
12,NUMBER
‐,O
Parameter,O
Models,O
see,O
supple,O
‐,O
mentary,O
materials,O
.,O
Epitope,ORGANIZATION
IgG,O
Epitope,O
IgM,O
Days,DURATION
PSO,O
No,O
.,O
of,O
positve,O
No,O
.,O
testing,O
1,NUMBER
.,O
For,O
sensitivity,O
of,O
Ragon,ORGANIZATION
/,ORGANIZATION
MGH,ORGANIZATION
IgM,ORGANIZATION
and,O
IgA,O
see,O
supplementary,O
materials,O
.,O
2,NUMBER
.,O
The,O
Roche,O
Elecsys,O
Anti,O
‐,O
SARS,O
‐,O
CoV,O
‐,O
2,NUMBER
immunoassay,O
detects,O
IgG,O
and,O
likely,O
IgM,O
and,O
IgA,O
;,O
details,O
of,O
other,O
isotypes,O
are,O
not,O
provided,O
by,O
manufacturer,TITLE
3,NUMBER
.,O
Sensitivity,O
of,O
the,O
Simoa,O
multiplex,O
assay,O
Early,O
Model,TITLE
.,O
For,O
sensitivities,O
of,O
the,O
Late,O
and,O
12,NUMBER
‐,O
Parameter,O
Models,O
see,O
supplementary,O
materials,O
.,O
